Value
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.5 |
| P/S | 5.7 |
| EV/EBITDA | 4.4 |
| Fwd P/E | 9.4 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 9.5x
- ▸PEG: 0.22
HALO · Why this verdict
Why Halozyme Therapeutics (HALO) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Halozyme offers a wide economic moat, 42% year-over-year revenue growth, and a forward P/E of 7.2x with a PEG of 0.23 — a combination suggesting the market has not fully priced its growth trajectory; the stock has reached the analyst consensus target with only 2.4% remaining upside from current levels, making the setup compelling at a pullback entry but stretched at spot.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business carries a wide economic moat, generates margins of 23%, a Rule of 40 score of 57, and a Piotroski F-Score of 8 out of 9 — a combination that describes a durable, high-quality franchise with strong operational discipline. Quality breakdown | Margins stay above 20% and the Rule of 40 remains above 40 over the next 12 months, sustaining the quality profile. | →Stable |
| CounterFree cash flow stands at only 65% of net income, below the 100% level that would fully validate earnings quality; if the gap between reported income and cash generation persists, the franchise's actual cash productivity is more moderate than the income statement implies. | ||
Revenue is expanding at 42% year-over-year while the stock trades at a forward P/E of 7.2x and a PEG of 0.23 — a rare pairing of high growth and low relative price that implies meaningful valuation catch-up potential if the growth rate is sustained. Growth breakdown | Revenue growth stays above 25% year-over-year for the next 2 quarters, sustaining the gap between growth rate and multiple. | ↑Improving |
| CounterLeverage near 9.9 times equity means growth must be sustained to service the debt load; any revenue deceleration would simultaneously reduce the growth premium justifying the current valuation and tighten financial flexibility. | ||
Three of the four most recent quarters produced earnings beats; however, the second most recent quarter produced an exceptionally large miss — with the actual result falling sharply below a consensus estimate of $2.20 — pulling the trailing average surprise negative and leaving guidance reliability an open question despite the most recent quarter returning to beat territory. Earnings | EPS positive surprises in each of the next 3 consecutive quarters, restoring a consistent beat pattern and rebuilding guidance credibility. | ↓Deteriorating |
| CounterA single large miss of this magnitude is often attributable to a discrete, non-recurring charge rather than a structural problem; the subsequent beat in the most recent quarter suggests the business quickly resumed normal execution. | ||
Leverage near 9.9 times equity combined with a 15% short interest creates a fragile setup where any negative revenue or earnings surprise could simultaneously tighten financial flexibility and trigger forced position covering that amplifies price declines. Key risks | Debt-to-equity ratio falls below 5x within 18 months as cash generation reduces the debt load. | ↑Improving |
| CounterA high short position can become a catalyst for a sharp move to the upside if results beat expectations — the same positioning that amplifies downside can fuel a rapid covering rally on a positive surprise. | ||
The business carries a wide economic moat, generates margins of 23%, a Rule of 40 score of 57, and a Piotroski F-Score of 8 out of 9 — a combination that describes a durable, high-quality franchise with strong operational discipline.
→StableQuality breakdown
- Expectation
- Margins stay above 20% and the Rule of 40 remains above 40 over the next 12 months, sustaining the quality profile.
CounterFree cash flow stands at only 65% of net income, below the 100% level that would fully validate earnings quality; if the gap between reported income and cash generation persists, the franchise's actual cash productivity is more moderate than the income statement implies.
Revenue is expanding at 42% year-over-year while the stock trades at a forward P/E of 7.2x and a PEG of 0.23 — a rare pairing of high growth and low relative price that implies meaningful valuation catch-up potential if the growth rate is sustained.
↑ImprovingGrowth breakdown
- Expectation
- Revenue growth stays above 25% year-over-year for the next 2 quarters, sustaining the gap between growth rate and multiple.
CounterLeverage near 9.9 times equity means growth must be sustained to service the debt load; any revenue deceleration would simultaneously reduce the growth premium justifying the current valuation and tighten financial flexibility.
Three of the four most recent quarters produced earnings beats; however, the second most recent quarter produced an exceptionally large miss — with the actual result falling sharply below a consensus estimate of $2.20 — pulling the trailing average surprise negative and leaving guidance reliability an open question despite the most recent quarter returning to beat territory.
↓DeterioratingEarnings
- Expectation
- EPS positive surprises in each of the next 3 consecutive quarters, restoring a consistent beat pattern and rebuilding guidance credibility.
CounterA single large miss of this magnitude is often attributable to a discrete, non-recurring charge rather than a structural problem; the subsequent beat in the most recent quarter suggests the business quickly resumed normal execution.
Leverage near 9.9 times equity combined with a 15% short interest creates a fragile setup where any negative revenue or earnings surprise could simultaneously tighten financial flexibility and trigger forced position covering that amplifies price declines.
↑ImprovingKey risks
- Expectation
- Debt-to-equity ratio falls below 5x within 18 months as cash generation reduces the debt load.
CounterA high short position can become a catalyst for a sharp move to the upside if results beat expectations — the same positioning that amplifies downside can fuel a rapid covering rally on a positive surprise.
Per-dimension breakdown
Quality
9.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 9.1 |
| FCF quality | 6.1 |
| Moat | 7.5 |
| Rule of 40 | 9.5 |
| Piotroski F | 8.9 |
- ▸Excellent ROE: 174%
- ▸Strong margins: 25%
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 48% YoY
Momentum
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.0 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 1.4 |
- ▸Overbought (RSI 80)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.0 |
| Analyst rating | 6.9 |
| Price target | 5.1 |
- ▸LLM news sentiment: -0.40 (n=3)
- ▸Light analyst coverage (9.0) — signal dampened
Insider
4.1/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.9 |
- ▸Modest insider selling — $3,755,641 (0.034% of mkt cap)
Peer rank
5.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.9 |
| quality rank | 8.6 |
| growth rank | 7.2 |
- ▸Superior ROE vs peers
Technical
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.1 |
| support resistance | 2.2 |
| 52w position | 8.8 |
Risk (lower is worse)
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.4 |
| days to cover | 2.4 |
| volatility | 3.6 |
| put call | 9.8 |
| implied vol | 3.1 |
| max pain risk | 5.0 |
| beta | 7.9 |
| debt equity | 0.0 |
- ▸Short squeeze setup: 16% short, quality 7.5
- ▸High IV: 62%
Catalyst
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 7.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.22, quality 9.1/10, growth 10.0/10).
Engine technical detail
verdict_path:
L4:PATH_C2_GARP_WAIT|ENTRY_STICKY:WITHIN_BANDPassed (6)
- MOMENTUM:5.1>=4.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:78d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.8=NEGATIVE
Warning (2)
- MOMENTUM:5.1<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.81
Upside
-12.2%
Downside
15.0%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The C-path quality+growth combination triggered the STRONG_BUY_WAIT verdict: quality 9.1 and growth 10.0 both clear their thresholds, with asymmetric R:R of -0.81 supporting the read.
The strongest dimensions are Growth at 10.0, Quality at 9.1, and Value at 6.4; the weakest are Insider at 4.1, Technical at 4.4, and Risk (lower is worse) at 4.9. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -0.81 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Quality Franchise
Trip ifGross margin falls below 15% for 2 consecutive quarters.
- P2High Growth Cheap Valuation
Trip ifRevenue growth falls below 20% year-over-year for 2 consecutive quarters.
- P3Earnings Execution Mixed Signal
Trip ifEPS positive surprise exceeds 5% for 3 consecutive quarters, restoring a consistent beat pattern and falsifying the mixed-signal characterization.
- P4Leverage Short Interest Vulnerability
Trip ifDebt-to-equity ratio falls below 5x, reducing the leverage overhang meaningfully.